JP2017517532A - 抗ウイルス化合物の固体形態 - Google Patents

抗ウイルス化合物の固体形態 Download PDF

Info

Publication number
JP2017517532A
JP2017517532A JP2016572253A JP2016572253A JP2017517532A JP 2017517532 A JP2017517532 A JP 2017517532A JP 2016572253 A JP2016572253 A JP 2016572253A JP 2016572253 A JP2016572253 A JP 2016572253A JP 2017517532 A JP2017517532 A JP 2017517532A
Authority
JP
Japan
Prior art keywords
compound
bis
imidazol
phosphate
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016572253A
Other languages
English (en)
Japanese (ja)
Inventor
オルガ ビクトロブナ ラピナ，
オルガ ビクトロブナ ラピナ，
ビン シ，
ビン シ，
ファン ワン，
ファン ワン，
スコット アラン ウォルケンハウアー，
スコット アラン ウォルケンハウアー，
Original Assignee
ギリアド ファーマセット エルエルシー
ギリアド ファーマセット エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアド ファーマセット エルエルシー, ギリアド ファーマセット エルエルシー filed Critical ギリアド ファーマセット エルエルシー
Publication of JP2017517532A publication Critical patent/JP2017517532A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016572253A 2014-06-11 2015-06-08 抗ウイルス化合物の固体形態 Withdrawn JP2017517532A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010919P 2014-06-11 2014-06-11
US62/010,919 2014-06-11
PCT/US2015/034649 WO2015191431A1 (en) 2014-06-11 2015-06-08 Solid forms of an antiviral compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019026534A Division JP2019070057A (ja) 2014-06-11 2019-02-18 抗ウイルス化合物の固体形態

Publications (1)

Publication Number Publication Date
JP2017517532A true JP2017517532A (ja) 2017-06-29

Family

ID=53443009

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016572253A Withdrawn JP2017517532A (ja) 2014-06-11 2015-06-08 抗ウイルス化合物の固体形態
JP2019026534A Ceased JP2019070057A (ja) 2014-06-11 2019-02-18 抗ウイルス化合物の固体形態
JP2019133593A Pending JP2019172711A (ja) 2014-06-11 2019-07-19 抗ウイルス化合物の固体形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019026534A Ceased JP2019070057A (ja) 2014-06-11 2019-02-18 抗ウイルス化合物の固体形態
JP2019133593A Pending JP2019172711A (ja) 2014-06-11 2019-07-19 抗ウイルス化合物の固体形態

Country Status (19)

Country Link
US (4) US9630972B2 (enExample)
EP (3) EP3154983B1 (enExample)
JP (3) JP2017517532A (enExample)
KR (3) KR20190007533A (enExample)
CN (1) CN106661042A (enExample)
AR (1) AR103194A1 (enExample)
AU (2) AU2015274961A1 (enExample)
BR (1) BR112016028843A2 (enExample)
CA (1) CA2951188C (enExample)
EA (1) EA201692220A1 (enExample)
ES (1) ES2785409T3 (enExample)
IL (1) IL249041A0 (enExample)
MX (1) MX2016016299A (enExample)
PL (1) PL3154983T3 (enExample)
PT (1) PT3154983T (enExample)
SG (1) SG11201609810YA (enExample)
SI (1) SI3154983T1 (enExample)
TW (1) TWI721947B (enExample)
WO (1) WO2015191431A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345659A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
JP5905020B2 (ja) 2010-11-17 2016-04-20 ギリアド ファーマセット エルエルシー 抗ウイルス化合物
PT3431477T (pt) 2011-11-16 2020-12-15 Gilead Pharmasset Llc Imidazolilimidazolos condensados como compostos antivirais
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
WO2018006811A1 (zh) * 2016-07-08 2018-01-11 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
CN106432253B (zh) * 2016-09-21 2019-06-14 上海众强药业有限公司 一种维帕他韦新晶型及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089933A1 (ja) * 2003-04-02 2004-10-21 Astellas Pharma Inc. フルオロベンズアミド誘導体の新規結晶
JP2007522172A (ja) * 2004-02-13 2007-08-09 サンド・アクチエンゲゼルシヤフト リン酸ロシグリタゾン及び多形体形態
JP2008513436A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態
WO2009022642A1 (ja) * 2007-08-10 2009-02-19 Mitsubishi Tanabe Pharma Corporation 新規なイソキノリン化合物の塩及びその結晶
JP2009536208A (ja) * 2006-05-05 2009-10-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 結晶性（３−シアノ−１ｈ−インドール−７−イル）−［４−（４−フルオロフェネチル）ピペラジン−１−イル］メタノンホスフェート
JP2009286694A (ja) * 2006-09-07 2009-12-10 Eisai R & D Management Co Ltd ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶
WO2013075029A1 (en) * 2011-11-16 2013-05-23 Gilead Sciences, Inc. Condensed imidazolylimidazoles as antiviral compounds
WO2013173488A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds inhibitors of hcv ns5b

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
EP1411928A1 (en) 2001-07-20 2004-04-28 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
MXPA05012101A (es) 2003-05-09 2006-02-08 Boehringer Ingelheim Int Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI442947B (zh) 2006-12-07 2014-07-01 Daiichi Sankyo Co Ltd 安定性經改善之薄膜塗覆製劑
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101468765B1 (ko) 2008-02-12 2014-12-04 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 바이러스 억제제
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2391600T3 (es) 2008-02-13 2012-11-28 Bristol-Myers Squibb Company Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C
EP2323631A1 (en) 2008-08-07 2011-05-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
BRPI0922366B8 (pt) 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
SG171890A1 (en) 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
MX2011008982A (es) 2009-02-27 2011-09-15 Enata Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
KR101387274B1 (ko) 2009-03-27 2014-04-25 머크 샤프 앤드 돔 코포레이션 Ｃ형 간염 바이러스 복제의 억제제
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
MX363732B (es) 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011075607A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US8609635B2 (en) 2010-03-09 2013-12-17 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2616461A4 (en) 2010-08-26 2014-03-26 Rfs Pharma Llc POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
KR101894704B1 (ko) 2010-09-21 2018-09-05 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
JP5905020B2 (ja) 2010-11-17 2016-04-20 ギリアド ファーマセット エルエルシー 抗ウイルス化合物
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US20130172239A1 (en) 2011-12-29 2013-07-04 Abbvie Inc. Solid compositions
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
TW201434949A (zh) 2013-01-31 2014-09-16 Nitto Denko Corp 環氧組合物及環氧樹脂成形體
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置
EP3588013A1 (de) 2018-06-26 2020-01-01 XelectriX Power GmbH Verfahren zur abgabe von elektrischer energie

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089933A1 (ja) * 2003-04-02 2004-10-21 Astellas Pharma Inc. フルオロベンズアミド誘導体の新規結晶
JP2007522172A (ja) * 2004-02-13 2007-08-09 サンド・アクチエンゲゼルシヤフト リン酸ロシグリタゾン及び多形体形態
JP2008513436A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態
JP2009536208A (ja) * 2006-05-05 2009-10-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 結晶性（３−シアノ−１ｈ−インドール−７−イル）−［４−（４−フルオロフェネチル）ピペラジン−１−イル］メタノンホスフェート
JP2009286694A (ja) * 2006-09-07 2009-12-10 Eisai R & D Management Co Ltd ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶
WO2009022642A1 (ja) * 2007-08-10 2009-02-19 Mitsubishi Tanabe Pharma Corporation 新規なイソキノリン化合物の塩及びその結晶
WO2013075029A1 (en) * 2011-11-16 2013-05-23 Gilead Sciences, Inc. Condensed imidazolylimidazoles as antiviral compounds
WO2013173488A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds inhibitors of hcv ns5b

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 「最新 創薬化学 下巻」, JPN6014029314, 1999, pages 347 - 65, ISSN: 0003901591 *
CAIRA M R, TOPICS IN CURRENT CHEMISTRY, vol. V198, JPN5006012237, 1998, DE, pages 163 - 208, ISSN: 0003901593 *
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0003901592 *
芦澤一英 編, 医薬品の多形現象と晶析の科学, JPN6012027421, 20 September 2002 (2002-09-20), pages 312 - 317, ISSN: 0003901594 *

Also Published As

Publication number Publication date
US20190270750A1 (en) 2019-09-05
US20170247386A1 (en) 2017-08-31
US9884873B2 (en) 2018-02-06
EP3822275A1 (en) 2021-05-19
AU2015274961A1 (en) 2016-12-01
EA201692220A1 (ru) 2017-05-31
ES2785409T3 (es) 2020-10-06
EP3154983A1 (en) 2017-04-19
CN106661042A (zh) 2017-05-10
CA2951188A1 (en) 2015-12-17
AU2018201948A1 (en) 2018-04-12
SG11201609810YA (en) 2016-12-29
US20150361085A1 (en) 2015-12-17
JP2019070057A (ja) 2019-05-09
PT3154983T (pt) 2020-05-06
EP3666775A1 (en) 2020-06-17
SI3154983T1 (sl) 2020-04-30
MX2016016299A (es) 2017-04-06
KR20200145852A (ko) 2020-12-30
US11203599B2 (en) 2021-12-21
WO2015191431A1 (en) 2015-12-17
EP3154983B1 (en) 2020-02-12
PL3154983T3 (pl) 2020-06-29
KR20170015506A (ko) 2017-02-08
US20200283449A1 (en) 2020-09-10
IL249041A0 (en) 2017-01-31
AU2018201948B2 (en) 2019-10-03
AR103194A1 (es) 2017-04-26
JP2019172711A (ja) 2019-10-10
US9630972B2 (en) 2017-04-25
KR20190007533A (ko) 2019-01-22
CA2951188C (en) 2019-09-24
TW201609745A (zh) 2016-03-16
US10604530B2 (en) 2020-03-31
TWI721947B (zh) 2021-03-21
BR112016028843A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
US11203599B2 (en) Solid forms of an antiviral compound
US9409891B2 (en) Solid forms of an antiviral compound
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
TW202404604A (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
JP6748123B2 (ja) サクビトリルカルシウム塩
AU2024208765A1 (en) Inhibitor of complement factor b
WO2019237957A1 (zh) 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
HK40031882A (en) Solid forms of an antiviral compound
HK1237346A1 (en) Solid forms of an antiviral compound
TWI906614B (zh) 某些mcl-1抑制劑之鹽及同質多形體
HK1236199A1 (en) Solid forms of an antiviral compound
HK1236199B (en) Solid forms of an antiviral compound
US20200283381A1 (en) Solid state forms of elafibranor
CN116745294A (zh) 酰胺噁唑类化合物
CN119255998A (zh) 特定mcl-1抑制剂的盐和多晶型物
CN117105923A (zh) 具有高生物利用度的鲁拉西酮盐及其制法和应用
CN101627031A (zh) 3-(1h-吲哚-3-基)-4-[2-(4-甲基-哌嗪-1-基)-喹唑啉-4-基]-吡咯-2,5-二酮的盐
JP2007505071A (ja) 結晶多形性ヌクレオシド化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190218

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190225

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190226

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190305